{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:54:39Z","timestamp":1778698479714,"version":"3.51.4"},"reference-count":70,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"None"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Treating men with Peyronie\u2019s disease remains a challenging problem facing clinicians working across urology and sexual medicine fields. Patients can often be left disappointed by current treatment paradigms, and an overall lack of suitable molecular targets has limited the options for novel, effective medical therapy. Managing men with Peyronie\u2019s disease often involves careful counselling alongside multifaceted and possible combination treatments to help improve symptoms whilst ameliorating potential side effects of therapy. We review the latest medical literature and evidence in the contemporary management of Peyronie\u2019s disease.<\/ns4:p>","DOI":"10.12688\/f1000research.20557.1","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T11:20:14Z","timestamp":1589973614000},"page":"381","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent advances in managing Peyronie\u2019s disease"],"prefix":"10.12688","volume":"9","author":[{"given":"Asrit","family":"Babu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-228X","authenticated-orcid":false,"given":"Oliver","family":"Kayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"727-30","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey.","volume":"88","author":"U Schwarzer","year":"2001","journal-title":"BJU Int."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"2350-3","DOI":"10.1097\/01.ju.0000127744.18878.f1","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.","volume":"171","author":"J Mulhall","year":"2004","journal-title":"J Urol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","article-title":"The Prevalence of Peyronie's Disease in the United States: A Population-Based Study.","volume":"11","author":"M Stuntz","year":"2016","journal-title":"PLoS One."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1376-9","DOI":"10.1016\/s0022-5347(17)39746-x","article-title":"The natural history of Peyronie's disease.","volume":"144","author":"M Gelbard","year":"1990","journal-title":"J Urol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"2115-8","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease.","volume":"175","author":"J Mulhall","year":"2006","journal-title":"J Urol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"10-6","DOI":"10.1016\/j.purol.2016.08.018","article-title":"Patient-reported long-term sexual outcomes following plication surgery for penile curvature: A retrospective 58-patient study.","volume":"27","author":"A Baldini","year":"2017","journal-title":"Prog Urol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"120-8","DOI":"10.1016\/j.jsxm.2015.12.004","article-title":"10 Years' Plaque Incision and Vein Grafting for Peyronie's Disease: Does Time Matter?","volume":"13","author":"F Wimpissinger","year":"2016","journal-title":"J Sex Med."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"117-31","DOI":"10.1007\/s11930-015-0045-y","article-title":"Peyronie's Disease: A Review of Etiology, Diagnosis, and Management.","volume":"7","author":"A Bilgutay","year":"2015","journal-title":"Curr Sex Health Rep."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"570-4","DOI":"10.1111\/j.1464-410X.2006.05969.x","article-title":"Risk factors for Peyronie's disease: a case-control study.","volume":"97","author":"M Bjekic","year":"2006","journal-title":"BJU Int."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1700-7","DOI":"10.1097\/00005392-199805000-00097","article-title":"The effect of surgical trauma on rat tunica albuginea.","volume":"159","author":"A El-Sakka","year":"1998","journal-title":"J Urol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1-6","DOI":"10.1080\/13685538.2019.1586870","article-title":"Supporting the role of penile trauma and micro-trauma in the etiology of Peyronie's disease. Prospective observational study using the electronic microscope to examine two types of plaques.","author":"A De Rose","year":"2019","journal-title":"Aging Male."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"79-97","DOI":"10.1038\/s41585-018-0109-7","article-title":"The mechanisms and potential of stem cell therapy for penile fibrosis.","volume":"16","author":"U Milenkovic","year":"2019","journal-title":"Nat Rev Urol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"244-51","DOI":"10.1111\/j.2047-2927.2013.00181.x","article-title":"Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease.","volume":"2","author":"A Gokce","year":"2014","journal-title":"Andrology."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1533-44","DOI":"10.1111\/jsm.12916","article-title":"Intratunical Injection of Genetically Modified Adipose Tissue-Derived Stem Cells with Human Interferon \u03b1-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis.","volume":"12","author":"A Gokce","year":"2015","journal-title":"J Sex Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"551-60","DOI":"10.1016\/j.eururo.2012.09.034","article-title":"Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease.","volume":"63","author":"F Castiglione","year":"2013","journal-title":"Eur Urol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"5149-5156","DOI":"10.3892\/etm.2017.5179","article-title":"Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells.","volume":"14","author":"H Jiang","year":"2017","journal-title":"Exp Ther Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"543-52","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature.","volume":"62","author":"K Hatzimouratidis","year":"2012","journal-title":"Eur Urol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"745-53","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie\u2019s Disease: AUA Guideline.","volume":"194","author":"A Nehra","year":"2015","journal-title":"J Urol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"905-23","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-Based Management Guidelines on Peyronie's Disease.","volume":"13","author":"E Chung","year":"2016","journal-title":"J Sex Med."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"530-6","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study.","volume":"47","author":"W Weidner","year":"2005","journal-title":"Eur Urol."},{"key":"ref-21","first-page":"61-7","article-title":"A multicentre double-blind controlled clinical trial of potassium para-amino-benzoate (POTABA1) in Peyronie\u2019s disease.","volume":"9","author":"P Shah","year":"1983","journal-title":"Progr Reprod Biol Med J."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"40-6","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.","volume":"34","author":"T Park","year":"2016","journal-title":"World J Mens Health."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"120-8","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases.","volume":"1","author":"G Paulis","year":"2013","journal-title":"Andrology."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"403-9","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study.","volume":"12","author":"G Paulis","year":"2013","journal-title":"Inflamm Allergy Drug Targets."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"129-39","DOI":"10.2147\/RRU.S141748","article-title":"Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.","volume":"9","author":"G Paulis","year":"2017","journal-title":"Res Rep Urol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1049-60","DOI":"10.1016\/j.bbadis.2012.09.014","article-title":"Cytokine mediated tissue fibrosis.","volume":"1832","author":"L Borthwick","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"478-84","DOI":"10.1007\/s11934-004-0074-y","article-title":"New discoveries in the basic science understanding of Peyronie's disease.","volume":"5","author":"M Jalkut","year":"2004","journal-title":"Curr Urol Rep."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"313-27","DOI":"10.1111\/jsm.12760","article-title":"The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.","volume":"12","author":"R Gelfand","year":"2015","journal-title":"J Sex Med."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"329-40","DOI":"10.1016\/j.eururo.2018.10.014","article-title":"Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.","volume":"75","author":"M Ilg","year":"2019","journal-title":"Eur Urol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"241-7","DOI":"10.1136\/gut.50.2.241","article-title":"Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.","volume":"50","author":"C Raetsch","year":"2002","journal-title":"Gut."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"322-5","DOI":"10.1038\/aja.2010.117","article-title":"Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.","volume":"13","author":"J Smith","year":"2010","journal-title":"Asian J Androl."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"23-30","DOI":"10.5539\/gjhs.v6n7p23","article-title":"Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline.","volume":"6","author":"M Alizadeh","year":"2014","journal-title":"Glob J Health Sci."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"240-8","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease.","volume":"106","author":"M Safarinejad","year":"2010","journal-title":"BJU Int."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"459-63","DOI":"10.1016\/j.esxm.2019.07.003","article-title":"Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease.","volume":"7","author":"A Ibrahim","year":"2019","journal-title":"Sex Med."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"135-40","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie's disease experimental studies.","volume":"10","author":"M Gelbard","year":"1982","journal-title":"Urol Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"199-207","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.","volume":"190","author":"M Gelbard","year":"2013","journal-title":"J Urol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1430-7","DOI":"10.1016\/j.jsxm.2017.08.015","article-title":"Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.","volume":"14","author":"D Ralph","year":"2017","journal-title":"J Sex Med."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"717-23","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.","volume":"120","author":"A Abdel Raheem","year":"2017","journal-title":"BJU Int."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"564-7","DOI":"10.1111\/andr.12497","article-title":"Collagenase clostridium histolyticum for the treatment of Peyronie's disease: A prospective Italian multicentric study.","volume":"6","author":"M Capece","year":"2018","journal-title":"Andrology."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"102-9","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical Experience With Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease.","volume":"104","author":"M Ziegelmann","year":"2017","journal-title":"Urology."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1472-7","DOI":"10.1016\/j.jsxm.2018.08.012","article-title":"Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie\u2019s Disease: A Matched-Pair Comparison Analysis.","volume":"15","author":"A Cocci","year":"2018","journal-title":"J Sex Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1523-8","DOI":"10.1007\/s40265-016-0649-1","article-title":"Collagenase Clostridium Histolyticum for the Treatment of Peyronie\u2019s Disease: A \u2018Real World\u2019 Clinical Perspective.","volume":"76","author":"J Anaissie","year":"2016","journal-title":"Drugs."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"660-1","DOI":"10.1016\/j.eururo.2019.11.019","article-title":"The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market.","volume":"77","author":"A Cocci","year":"2020","journal-title":"Eur Urol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"620-6","DOI":"10.1016\/s0090-4295(97)00700-0","article-title":"Use of Intralesional Verapamil to Dissolve Peyronie\u2019s Disease Plaque: A Long-Term Single-Blind Study.","volume":"51","author":"J Rehman","year":"1998","journal-title":"Urology."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"467-71","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study.","volume":"41","author":"M Shirazi","year":"2009","journal-title":"Int Urol Nephrol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"248-58","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: A phase 3 open-label study.","volume":"12","author":"L Levine","year":"2015","journal-title":"J Sex Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"771-5","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: Preliminary results from a prospective, double-blinded, randomized study.","volume":"5","author":"V Favilla","year":"2017","journal-title":"Andrology."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"972-5","DOI":"10.1016\/j.juro.2006.10.065","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie's disease: A double-blind, placebo controlled trial.","volume":"177","author":"J Greenfield","year":"2007","journal-title":"J Urol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"129-32","DOI":"10.1111\/j.2047-2927.2012.00018.x","article-title":"Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease.","volume":"1","author":"A Mehrsai","year":"2013","journal-title":"Andrology."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"288-95","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease.","volume":"9","author":"M Abern","year":"2012","journal-title":"J Sex Med."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"709-15","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease.","volume":"2","author":"M Kendirci","year":"2005","journal-title":"J Sex Med."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"394-8","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease.","volume":"176","author":"W Hellstrom","year":"2006","journal-title":"J Urol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"754-8","DOI":"10.1016\/j.juro.2015.03.092","article-title":"The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease.","volume":"194","author":"F Yafi","year":"2015","journal-title":"J Urol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"154-158","DOI":"10.4103\/UA.UA_65_17","article-title":"Prospective study to evaluate the clinical outcome of intralesional interferon-\u03b1 2b in the management of Peyronie's disease.","volume":"10","author":"A Sokhal","year":"2018","journal-title":"Urol Ann."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1595-602","DOI":"10.1007\/s11255-015-1074-1","article-title":"Intralesional hyaluronic acid: An innovative treatment for Peyronie's disease.","volume":"47","author":"R Gennaro","year":"2015","journal-title":"Int Urol Nephrol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"e83-8","DOI":"10.1016\/j.esxm.2016.01.002","article-title":"Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study.","volume":"4","author":"A Zucchi","year":"2016","journal-title":"Sex Med."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"767-81","DOI":"10.1016\/j.eururo.2018.07.005","article-title":"Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature.","volume":"74","author":"G Russo","year":"2018","journal-title":"Eur Urol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1259-67","DOI":"10.1111\/jsm.12082","article-title":"Peyronie's Disease and Mechanotransduction: An In Vitro Analysis of the Cellular Changes to Peyronie's Disease in a Cell-Culture Strain System.","volume":"10","author":"E Chung","year":"2013","journal-title":"J Sex Med."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"517-26","DOI":"10.1080\/17434440.2018.1502083","article-title":"Devices for penile traction: The long and winding road to treating Peyronie's disease.","volume":"15","author":"S Setia","year":"2018","journal-title":"Expert Rev Med Devices."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"558-66","DOI":"10.1111\/j.1743-6109.2008.01108.x","article-title":"Use of Penile Extender Device in the Treatment of Penile Curvature as a Result of Peyronie's Disease. Results of a Phase II Prospective Study.","volume":"6","author":"P Gontero","year":"2009","journal-title":"J Sex Med."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"506-15","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie's disease management with traction device: A nonrandomized prospective controlled trial with ultrasound correlation.","volume":"11","author":"J Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"694-702","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u2018Penimaster PRO\u2019 is effective and safe in the stable phase of Peyronie's disease: A controlled multicentre study.","volume":"123","author":"I Moncada","year":"2019","journal-title":"BJU Int."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"599-610","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial.","volume":"202","author":"M Ziegelmann","year":"2019","journal-title":"J Urol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"891-900","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie\u2019s Disease.","volume":"16","author":"M Alom","year":"2019","journal-title":"J Sex Med."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"161-6","DOI":"10.1038\/ijir.2016.24","article-title":"A meta-analysis of extracorporeal shock wave therapy for Peyronie\u2019s disease.","volume":"28","author":"L Gao","year":"2016","journal-title":"Int J Impot Res."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"28-30","DOI":"10.5301\/RU.2013.10599","article-title":"Peyronie's disease: Endocavernous plaque excision without substitutive graft: critical 5-year experience.","volume":"80","author":"F Mantovani","year":"2013","journal-title":"Urologia."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"1593-8","DOI":"10.1111\/jsm.12530","article-title":"High Patient Satisfaction of Inflatable Penile Prosthesis Insertion with Synchronous Penile Plication for Erectile Dysfunction and Peyronie's Disease.","volume":"11","author":"P Chung","year":"2014","journal-title":"J Sex Med."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"117-26","DOI":"10.1111\/andr.12421","article-title":"Grafts for Peyronie's disease: A comprehensive review.","volume":"6","author":"B Garcia-Gomez","year":"2018","journal-title":"Andrology."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"1061-1062","DOI":"10.1016\/j.jsxm.2018.04.646","article-title":"A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease.","volume":"15","author":"M Falcone","year":"2018","journal-title":"J Sex Med."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"256-62","DOI":"10.1038\/s41443-018-0071-1","article-title":"Long-term outcome after grafting with small intestinal submucosa and collagen fleece in patients with Peyronie's disease: A matched pair analysis.","volume":"31","author":"B Rosenhammer","year":"2019","journal-title":"Int J Impot Res."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-381\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-381\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-381\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T10:15:09Z","timestamp":1590488109000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-381\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":70,"URL":"https:\/\/doi.org\/10.12688\/f1000research.20557.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.22598.r63496","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22598.r63497","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-381\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.22598.r63497, Wayne J. G. Hellstrom, Ayad A. Yousif, Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA, 26 May 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-381\/v1#referee-response-63497","order":0,"name":"referee-response-63497","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22598.r63496, Alexander W. Pastuszak, Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA, 26 May 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-381\/v1#referee-response-63496","order":1,"name":"referee-response-63496","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}